Bard Makes Presence Felt in Hemostat Market with Medafor Acquisition

C. R. Bard, Inc. is to acquire privately-held Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. The purchase price of $200 million will be paid at closing, expected to occur later this year, and future contingent payments up to an additional $80 million are based on specific revenue-based milestones through June 30, 2015.